Global policy and access to new hepatitis C therapies for people who inject drugs

Joseph S. Doyle; Esther Aspinall; Sharon Hutchinson; Brendan Quinn; Charles Gore; Stefan Wiktor; Margaret E. Hellard

doi:10.1016/j.drugpo.2015.05.008

Global policy and access to new hepatitis C therapies for people who inject drugs

Joseph S. Doyle, Esther Aspinall, Sharon Hutchinson, Brendan Quinn, Charles Gore, Stefan Wiktor, Margaret E. Hellard

SHLS School Office

Research output: Contribution to journal › Article › peer-review

158 Downloads (Pure)

Abstract

People who inject drugs (PWID) are disproportionately affected by hepatitis C virus (HCV). This review outlines policy recommendations made in the 2014 World Health Organisation (WHO) Guidelines on Screening, Care and Treatment of HCV and their relevance to PWID. It also canvasses issues that will affect translation of these global guidelines into practice. The first global HCV guidelines released by WHO have recently advocated targeted HCV testing for PWID, assessment of liver disease and support for alcohol reduction during care. They also strongly advocate treatment using currently licensed direct-acting antiviral agents for all individuals, in particular PWID as a key affected population. New HCV treatment regimens have the potential to cure more than 90% of treated individuals. Scaling-up treatment among PWID has the potential to improve individual and population health by reducing HCV transmission, improving quality of life and supporting behaviour modifications that lead to less risk-taking over time.

Original language	English
Pages (from-to)	1064-1071
Number of pages	8
Journal	International Journal of Drug Policy
Volume	26
Issue number	11
Early online date	1 Jun 2015
DOIs	https://doi.org/10.1016/j.drugpo.2015.05.008
Publication status	Published - Nov 2015

Keywords

hepatitis C
injecting drug users
therapy

Documents and Links

10.1016/j.drugpo.2015.05.008

Doyle, JS et al (2015) Global policy and access to new hepatitis C therapies for people who inject drugs
This is the author final version of an article originally published in: International Journal of Drug Policy (2015), 26 (11), pp.1064–1071 by Elsevier. The publisher version of the article can be accessed via the DOI link below. Copyright © 2015. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Accepted author manuscript, 345 KB

Fingerprint Dive into the research topics of 'Global policy and access to new hepatitis C therapies for people who inject drugs'. Together they form a unique fingerprint.

Cite this

@article{e7093eddf4704155a9779e69dccbf337,

title = "Global policy and access to new hepatitis C therapies for people who inject drugs",

abstract = "People who inject drugs (PWID) are disproportionately affected by hepatitis C virus (HCV). This review outlines policy recommendations made in the 2014 World Health Organisation (WHO) Guidelines on Screening, Care and Treatment of HCV and their relevance to PWID. It also canvasses issues that will affect translation of these global guidelines into practice. The first global HCV guidelines released by WHO have recently advocated targeted HCV testing for PWID, assessment of liver disease and support for alcohol reduction during care. They also strongly advocate treatment using currently licensed direct-acting antiviral agents for all individuals, in particular PWID as a key affected population. New HCV treatment regimens have the potential to cure more than 90% of treated individuals. Scaling-up treatment among PWID has the potential to improve individual and population health by reducing HCV transmission, improving quality of life and supporting behaviour modifications that lead to less risk-taking over time.",

keywords = "hepatitis C, injecting drug users, therapy",

author = "Doyle, {Joseph S.} and Esther Aspinall and Sharon Hutchinson and Brendan Quinn and Charles Gore and Stefan Wiktor and Hellard, {Margaret E.}",

note = "FT provided by email from SHLS administrator, publisher requires 12m embargo ET 11-12-15 Updated rights statement with CC licence as in RoMEO 6-6-16 ",

year = "2015",

month = nov,

doi = "10.1016/j.drugpo.2015.05.008",

language = "English",

volume = "26 ",

pages = "1064--1071",

journal = "International Journal of Drug Policy",

issn = "0955-3959",

publisher = "Elsevier B.V.",

number = "11",

}

TY - JOUR

T1 - Global policy and access to new hepatitis C therapies for people who inject drugs

AU - Doyle, Joseph S.

AU - Aspinall, Esther

AU - Hutchinson, Sharon

AU - Quinn, Brendan

AU - Gore, Charles

AU - Wiktor, Stefan

AU - Hellard, Margaret E.

N1 - FT provided by email from SHLS administrator, publisher requires 12m embargo ET 11-12-15 Updated rights statement with CC licence as in RoMEO 6-6-16

PY - 2015/11

Y1 - 2015/11

N2 - People who inject drugs (PWID) are disproportionately affected by hepatitis C virus (HCV). This review outlines policy recommendations made in the 2014 World Health Organisation (WHO) Guidelines on Screening, Care and Treatment of HCV and their relevance to PWID. It also canvasses issues that will affect translation of these global guidelines into practice. The first global HCV guidelines released by WHO have recently advocated targeted HCV testing for PWID, assessment of liver disease and support for alcohol reduction during care. They also strongly advocate treatment using currently licensed direct-acting antiviral agents for all individuals, in particular PWID as a key affected population. New HCV treatment regimens have the potential to cure more than 90% of treated individuals. Scaling-up treatment among PWID has the potential to improve individual and population health by reducing HCV transmission, improving quality of life and supporting behaviour modifications that lead to less risk-taking over time.

AB - People who inject drugs (PWID) are disproportionately affected by hepatitis C virus (HCV). This review outlines policy recommendations made in the 2014 World Health Organisation (WHO) Guidelines on Screening, Care and Treatment of HCV and their relevance to PWID. It also canvasses issues that will affect translation of these global guidelines into practice. The first global HCV guidelines released by WHO have recently advocated targeted HCV testing for PWID, assessment of liver disease and support for alcohol reduction during care. They also strongly advocate treatment using currently licensed direct-acting antiviral agents for all individuals, in particular PWID as a key affected population. New HCV treatment regimens have the potential to cure more than 90% of treated individuals. Scaling-up treatment among PWID has the potential to improve individual and population health by reducing HCV transmission, improving quality of life and supporting behaviour modifications that lead to less risk-taking over time.

KW - hepatitis C

KW - injecting drug users

KW - therapy

U2 - 10.1016/j.drugpo.2015.05.008

DO - 10.1016/j.drugpo.2015.05.008

M3 - Article

VL - 26

SP - 1064

EP - 1071

JO - International Journal of Drug Policy

JF - International Journal of Drug Policy

SN - 0955-3959

IS - 11

ER -